PMSG-Net: A priori-guided multilevel graph transformer fusion network for immunotherapy efficacy prediction
Author:
Funder
National Natural Science Foundation of China
Applied Basic Research Project of Shanxi Province, China
Publisher
Elsevier BV
Subject
Health Informatics,Computer Science Applications
Reference55 articles.
1. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer;Horn;N. Engl. J. Med.,2018
2. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial;Kato;Lancet Oncol.,2019
3. Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the CheckMate 143 phase 3 randomized clinical trial;Reardon;JAMA Oncol.,2020
4. First- line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial;Janjigian;Lancet,2021
5. Combination therapy with PD-1/PD-L1 blockade in non-small cell lung cancer: strategies and mechanisms;Huang;Pharmacol. Therapeut.,2021
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"全球学者库"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前全球学者库共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2023 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3